Multikinase inhibitor tablets developed by pharmaceutical manufacturers for hepatocellular carcinoma and renal cell carcinoma. Procured by oncology procurement professionals for hospital formularies. Distributed through B2B networks to support systemic therapy in advanced solid tumor cases at cancer centers.